title: Pre-clinical immunogenicity of human papillomavirus alpha-7 and alpha-9 major capsid proteins.
abstract: Human papillomavirus (HPV) vaccines confer protection against the oncogenic genotypes HPV16 and HPV18 through the generation of type-specific neutralizing antibodies raised against the constituent virus-like particles (VLP) based upon the major capsid proteins (L1) of these genotypes. The vaccines also confer a degree of cross-protection against some genetically related types from the Alpha-9 (HPV16-like: HPV31, HPV33, HPV35, HPV52, HPV58) and Alpha-7 (HPV18-like: HPV39, HPV45, HPV59, HPV68) species groups. The mechanism of cross-protection is unclear but may involve antibodies capable of recognizing shared inter-genotype epitopes. The relationship(s) between the genetic and antigenic diversity of the L1 protein, particularly for non-vaccine genotypes, is poorly understood. We carried out a comprehensive evaluation of the immunogenicity of L1 VLP derived from genotypes within the Alpha-7 and Alpha-9 species groups in New Zealand White rabbits and used L1L2 pseudoviruses as the target antigens in neutralization assays. The majority antibody response against L1 VLP was type-specific, as expected, but several instances of robust cross-neutralization were nevertheless observed including between HPV33 and HPV58 within the Alpha-9 species and between HPV39, HPV59 and HPV68 in the Alpha-7 species. Immunization with an experimental tetravalent preparation comprising VLP based upon HPV16, HPV18, HPV39 and HPV58 was capable of generating neutralizing antibodies against all the Alpha-7 and Alpha-9 genotypes. Competition of HPV31 and HPV33 cross-neutralizing antibodies in the tetravalent sera confirmed that these antibodies originated from HPV16 and HPV58 VLP, respectively, and suggested that they represent minority specificities within the antibody repertoire generated by the immunizing antigen. These data improve our understanding of the antigenic diversity of the L1 protein per se and may inform the rational design of a next generation vaccine formulation based upon empirical data.
authors.affiliation: Virus Reference Department, Public Health England, London, UK.
authors.forename: Sara L
authors.initials: SL
authors.lastname: Bissett
authors.affiliation: Division of Virology, National Institute for Biological Standards and Control, Potters Bar, UK.
authors.forename: Giada
authors.initials: G
authors.lastname: Mattiuzzo
authors.affiliation: Virus Reference Department, Public Health England, London, UK.
authors.forename: Eve
authors.initials: E
authors.lastname: Draper
authors.affiliation: Virus Reference Department, Public Health England, London, UK.
authors.forename: Anna
authors.initials: A
authors.lastname: Godi
authors.affiliation: Division of Virology, National Institute for Biological Standards and Control, Potters Bar, UK.
authors.forename: Dianna E
authors.initials: DE
authors.lastname: Wilkinson
authors.affiliation: Division of Virology, National Institute for Biological Standards and Control, Potters Bar, UK.
authors.forename: Philip
authors.initials: P
authors.lastname: Minor
authors.affiliation: Division of Virology, National Institute for Biological Standards and Control, Potters Bar, UK.
authors.forename: Mark
authors.initials: M
authors.lastname: Page
authors.affiliation: Virus Reference Department, Public Health England, London, UK. Electronic address: simon.beddows@phe.gov.uk.
authors.forename: Simon
authors.initials: S
authors.lastname: Beddows
mesh_terms: D052685:Alphapapillomavirus / Q000235:genetics* / Q000276:immunology; D000818:Animals; D057134:Antibodies, Neutralizing / Q000097:blood; D000914:Antibodies, Viral / Q000097:blood; D036022:Capsid Proteins / Q000276:immunology*; D056738:Cross Protection; D005260:Female; D005838:Genotype; D057809:HEK293 Cells; D006801:Humans; D008807:Mice, Inbred BALB C; D009500:Neutralization Tests; D009856:Oncogene Proteins, Viral / Q000276:immunology*; D053918:Papillomavirus Vaccines / Q000276:immunology*; D011817:Rabbits
chemical_list: D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral; D036022:Capsid Proteins; D009856:Oncogene Proteins, Viral; D053918:Papillomavirus Vaccines
keywords: Antibody; Antigenicity; Diversity; Human papillomavirus; L1; Major capsid protein